Partner Courtenay Brinckerhoff was quoted in a Law360 article, “4 Things To Know About Plan To Speed COVID-19 Patent Apps,” about a new U.S. Patent and Trademark Office program prioritizing the examination of COVID-19-related patent applications from small businesses.
Brinckerhoff said the program, which will fast-track certain patent applications related to the pandemic without requiring payment of the additional fees an accelerated examination usually requires, appears to be an attempt by the USPTO to provide help to companies that need it most.
“I think they’re balancing interests, so on the one hand, they want to help promote innovation in this area,” she said. “But on the other hand, they are a user-fee-funded agency, so they probably made the calculation that if big companies have promising coronavirus inventions that they want granted quickly, they can pay the fee” for an expedited review.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”